These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38753300)

  • 1. Genotype-specific development of MEN 2 constituent components in 683 RET carriers.
    Machens A; Lorenz K; Weber F; Brandenburg T; Führer-Sakel D; Dralle H
    Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38753300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
    Mathiesen JS; Habra MA; Bassett JHD; Choudhury SM; Balasubramanian SP; Howlett TA; Robinson BG; Gimenez-Roqueplo AP; Castinetti F; Vestergaard P; Frank-Raue K
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2069-2074. PubMed ID: 28323957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
    Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
    Frank-Raue K; Rybicki LA; Erlic Z; Schweizer H; Winter A; Milos I; Toledo SP; Toledo RA; Tavares MR; Alevizaki M; Mian C; Siggelkow H; Hüfner M; Wohllk N; Opocher G; Dvořáková S; Bendlova B; Czetwertynska M; Skasko E; Barontini M; Sanso G; Vorländer C; Maia AL; Patocs A; Links TP; de Groot JW; Kerstens MN; Valk GD; Miehle K; Musholt TJ; Biarnes J; Damjanovic S; Muresan M; Wüster C; Fassnacht M; Peczkowska M; Fauth C; Golcher H; Walter MA; Pichl J; Raue F; Eng C; Neumann HP;
    Hum Mutat; 2011 Jan; 32(1):51-8. PubMed ID: 20979234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
    Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
    Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
    Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
    Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.
    Greenberg LA
    Prim Care; 2024 Sep; 51(3):483-494. PubMed ID: 39067973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
    Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
    Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families.
    Valente FO; Dias da Silva MR; Camacho CP; Kunii IS; Bastos AU; da Fonseca CC; Simião HP; Tamanaha R; Maciel RM; Cerutti JM
    J Endocrinol Invest; 2013 Dec; 36(11):975-81. PubMed ID: 23723040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
    Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
    Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.
    Thosani S; Ayala-Ramirez M; Palmer L; Hu MI; Rich T; Gagel RF; Cote G; Waguespack SG; Habra MA; Jimenez C
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1813-9. PubMed ID: 24030942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary medullary thyroid carcinoma syndromes: experience from western India.
    Diwaker C; Sarathi V; Jaiswal SK; Shah R; Deshmukh A; Thomas AE; Prakash G; Malhotra G; Patil V; Lila A; Shah N; Bandgar T
    Fam Cancer; 2021 Jul; 20(3):241-251. PubMed ID: 33392850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.
    Elston MS; Meyer-Rochow GY; Holdaway I; Conaglen JV
    Horm Metab Res; 2012 May; 44(5):339-42. PubMed ID: 22274720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
    Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.